• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Data backs Boston Scientific Acurate neo2 aortic valve

Data backs Boston Scientific Acurate neo2 aortic valve

November 28, 2022 By Sean Whooley

Boston Scientific Acurate Neo2 heart valve
Acurate Neo2 [Image from Boston Scientific]
Boston Scientific (NYSE:BSX) announced positive results from its post-market clinical follow-up study for the Acurate neo2 aortic valve system.

Marlborough, Massachusetts-based Boston Scientific’s findings included a high procedural success rate of 98.4% for the TAVR system. In addition, the study observed low rates of mortality and paravalvular leak (PVL).

Findings, presented at PCR London Valves 2022, simultaneously published in EuroIntervention, according to a news release.

The European study included a primary safety endpoint of all-cause mortality set at 0.8% at 30 days. Data also demonstrated that no patients experienced greater than moderate PVL. It found that 1.9% experienced moderate PVL, and 18.9% experienced mild PVL. Other findings included a low 6.5% rate of new pacemaker implantation at 30 days post-procedure. Boston Scientific’s device demonstrated no disabling stroke or acute kidney injury incidence.

“With this foundational data set, we now have post-market surveillance results that validate the use of the current-generation Acurate neo2 valve for the management of patients with severe aortic stenosis,” said Dr. Lars Søndergaard, professor of cardiology, Department of Cardiology, Rigshospitalet and study co-principal investigator. “The data suggest that the annular sealing technology minimizes leakage around the valve – providing greater improvement in PVL than observed with the prior-generation Acurate neo valve – all while maintaining single-digit permanent pacemaker rates, which contributes to better long-term patient outcomes.”

About the study

The single-arm, prospective study includes 250 patients with severe aortic stenosis across 18 European centers. The study evaluates outcomes for five years post-procedure. Also, it includes a primary imaging endpoint to assess the visually apparent thickening of the prosthetic valve leaflets (HALT).

Boston Scientific said the reported halt rate at 30 days post-procedure came in at 24.5%. That falls within the range presented in previous TAVR trials with competitive devices.

Acurate neo2 received CE mark approval in 2020. Currently, Boston Scientific is enrolling in an investigational device exemption trial in the U.S. and Canada.

The latest data follows multiple presentations this year highlighting success with Acurate neo2. In June, study results demonstrated positive hemodynamic performance and clinical outcomes. In May, Boston Scientific presented a study evaluating a novel implant technique. It showed that commissural alignment could be achieved safely, effectively and quickly.

“These trial data confirm the success of meaningful and differentiated enhancements included in the design of the Acurate neo2 valve, from low rates of PVL and first-time pacemaker implantation to excellent hemodynamic performance and high rates of procedural success and safety,” said Dr. Ian Meredith, global CMO, Boston Scientific. “We look forward to reviewing longer-term results from this trial and bringing this differentiated TAVR technology to more patients and their physicians.”

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Implants, News Well, Replacement Heart Valves, Structural Heart Tagged With: Boston Scientific, tavr

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy